Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A) Proposed new ANA result interpretation algorithm that includes the anti-DFS70 results. (A) Proposed new ANA result interpretation algorithm that includes.

Published byDennis Cook Modified over 6 years ago

Similar presentations

Presentation on theme: "(A) Proposed new ANA result interpretation algorithm that includes the anti-DFS70 results. (A) Proposed new ANA result interpretation algorithm that includes."— Presentation transcript:

1 (A) Proposed new ANA result interpretation algorithm that includes the anti-DFS70 results.
(A) Proposed new ANA result interpretation algorithm that includes the anti-DFS70 results. (B) Proposed new ANA test algorithm considering anti-DFS70 antibodies on all ANA-positive samples. ANA: antinuclear antibodies; DFS: dense fine speckled; ENA: extractable nuclear antigen; SARD: systemic autoimmune rheumatic diseases. STACEY LUCAS et al. J Rheumatol 2018;45: ©2018 by The Journal of Rheumatology

Download ppt "(A) Proposed new ANA result interpretation algorithm that includes the anti-DFS70 results. (A) Proposed new ANA result interpretation algorithm that includes."

Similar presentations

Anti-nuclear antibodies

Anti-nuclear antibodies

ANTI-Ro/SSA 52 ANTIBODIES IN AUTOIMMUNE DISEASES Coordinator: Monica Copotoiu MD,PhD First author: Gabriela Mihai Coauthors: Isabela Micu, Mihaela Budianu,

ANTI-Ro/SSA 52 ANTIBODIES IN AUTOIMMUNE DISEASES Coordinator: Monica Copotoiu MD,PhD First author: Gabriela Mihai Coauthors: Isabela Micu, Mihaela Budianu,
3. AUTOIMMUNITY Immune Mechanisms Tolerance 4. Rheumatologic diseases

3. AUTOIMMUNITY Immune Mechanisms Tolerance 4. Rheumatologic diseases
Copyright © 2004 American Medical Association. All rights reserved.

Copyright © 2004 American Medical Association. All rights reserved.
Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 1 Induction of immune tolerance

Figure 1 Induction of immune tolerance
by Victor R. Gordeuk, Oswaldo L. Castro, and Roberto F. Machado

by Victor R. Gordeuk, Oswaldo L. Castro, and Roberto F. Machado
Selective left coronary angiography demonstrating normal left anterior descending (LAD) and left circumflex arteries and their branches (A). Selective.

Selective left coronary angiography demonstrating normal left anterior descending (LAD) and left circumflex arteries and their branches (A). Selective.
Figure 2 Targeted versus untargeted metabolomics approaches

Figure 2 Targeted versus untargeted metabolomics approaches
Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 4 Antinuclear antibodies and disease activity in SLE
Figure 3 Transcriptome studies performed in the target

Figure 3 Transcriptome studies performed in the target
Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.

Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.
Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 2 Shared genetic loci in systemic autoimmune diseases
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.
Percentage of patients achieving minimal disease activity (MDA): A

Percentage of patients achieving minimal disease activity (MDA): A

Similar presentations

Ads by Google